Drugs Made In America Acquisition Corp. (DMAAR) Non-Current Deffered Revenue (2025 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Non-Current Deffered Revenue for 2 consecutive years, with $6.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deffered Revenue fell 10.26% year-over-year to $6.2 million; the trailing twelve-month figure through Jun 2026 stood at $6.2 million (down 10.26% YoY), and the FY2025 full-year result was $6.9 million, changed N/A from the prior year.
• Non-Current Deffered Revenue eased to $6.2 million in Q2 2026 per DMAAR's latest filing, from $6.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $6.9 million in Q1 2025 and bottomed at $6.2 million in Q2 2026.